- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Schering completes Diatide purchase
The radiopharmaceutical industry was further consolidated last month when Schering AG’s subsidiary, Schering Berlin, announced that it has completed the purchase of 94% of the outstanding shares of peptide imaging agent developer Diatide of
The radiopharmaceutical industry was further consolidated last month when Schering AGs subsidiary, Schering Berlin, announced that it has completed the purchase of 94% of the outstanding shares of peptide imaging agent developer Diatide of Londonderry, NH. Schering Berlins tender offer, made through its subsidiary, BXA Acquisition, in September (SCAN 9/29/99), expired Oct. 22 without challenge. Schering Berlin will acquire the remaining untendered Diatide shares under another merger agreement that does not require shareholder approval. The deal is estimated at $130 million, and should be advantageous to both firms: While Diatide gains marketing and financial support, Schering gains access to Diatides R&D pipeline.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
